Invention Grant
- Patent Title: EAAT2 enhancing molecules
-
Application No.: US16630677Application Date: 2018-07-12
-
Publication No.: US11377436B2Publication Date: 2022-07-05
- Inventor: Kevin Hodgetts , Chien-Liang Glenn Lin
- Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC. , OHIO STATE UNIVERSITY
- Applicant Address: US MA Boston; US OH Columbus
- Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.,OHIO STATE UNIVERSITY
- Current Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.,OHIO STATE UNIVERSITY
- Current Assignee Address: US MA Boston; US OH Columbus
- Agency: Meunier Carlin & Curfman LLC
- International Application: PCT/US2018/041844 WO 20180712
- International Announcement: WO2019/014460 WO 20190117
- Main IPC: C07D401/04
- IPC: C07D401/04 ; A61P25/28 ; C07D213/75 ; C07D239/42 ; C07D241/18 ; C07D241/20 ; C07D401/14 ; C07D413/14 ; C07D417/14
Abstract:
The present application provides pyridine, pyrimidine, and pyrazine derivatives that activate excitatory amino acid transporter 2 (EAAT2), and methods of using the derivatives for treating or preventing diseases, disorders, and conditions associated with glutamate excitotoxicity.
Public/Granted literature
- US20210163440A1 EAAT2 ENHANCING MOLECULES Public/Granted day:2021-06-03
Information query
